LiuM, LiXC, LuL, CaoY, SunRR, ChenS,
et al.
: Cardiovascular disease and its relationship with chronic kidney disease. Eur Rev Med Pharmacol Sci18: 2918–2926, 2014PubMed
LiuM, LiXC, LuL, CaoY, SunRR, ChenS, : Cardiovascular disease and its relationship with chronic kidney disease. Eur Rev Med Pharmacol Sci18: 2918–2926, 2014PubMed)| false
TintutY, AlfonsoZ, SainiT, RadcliffK, WatsonK, BoströmK,
et al.
: Multilineage potential of cells from the artery wall. Circulation108: 2505–2510, 2003PubMed
PalmerSC, HayenA, MacaskillP, PellegriniF, CraigJC, ElderGJ,
et al.
: Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA305: 1119–1127, 2011PubMed
PalmerSC, HayenA, MacaskillP, PellegriniF, CraigJC, ElderGJ, : Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA305: 1119–1127, 2011PubMed10.1001/jama.2011.308)| false
SageAP, LuJ, TintutY, DemerLL: Hyperphosphatemia-induced nanocrystals upregulate the expression of bone morphogenetic protein-2 and osteopontin genes in mouse smooth muscle cells in vitro. Kidney Int79: 414–422, 2011PubMed
SageAP, LuJ, TintutY, DemerLL: Hyperphosphatemia-induced nanocrystals upregulate the expression of bone morphogenetic protein-2 and osteopontin genes in mouse smooth muscle cells in vitro. Kidney Int79: 414–422, 2011PubMed10.1038/ki.2010.390)| false
SchaferC, HeissA, SchwarzA, WestenfeldR, KettelerM, FloegeJ,
et al.
: The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest112: 357–366, 2003PubMed
SchurgersLJ, BarretoDV, BarretoFC, LiabeufS, RenardC, MagdeleynsEJ,
et al.
: The circulating inactive form of matrix gla protein is a surrogate marker for vascular calcification in chronic kidney disease: a preliminary report. Clin J Am Soc Nephrol5: 568–575, 2010PubMed
SchurgersLJ, BarretoDV, BarretoFC, LiabeufS, RenardC, MagdeleynsEJ, : The circulating inactive form of matrix gla protein is a surrogate marker for vascular calcification in chronic kidney disease: a preliminary report. Clin J Am Soc Nephrol5: 568–575, 2010PubMed10.2215/CJN.07081009)| false
SilvaAP, ViegasCS, MendesF, MacedoA, GuilhermeP, TavaresN,
et al.
: Gla-Rich Protein (GRP) as an Early and Novel Marker of Vascular Calcification and Kidney Dysfunction in Diabetic Patients with CKD: A Pilot Cross-Sectional Study. J Clin Med9: E635, 2020PubMed
SilvaAP, ViegasCS, MendesF, MacedoA, GuilhermeP, TavaresN, : Gla-Rich Protein (GRP) as an Early and Novel Marker of Vascular Calcification and Kidney Dysfunction in Diabetic Patients with CKD: A Pilot Cross-Sectional Study. J Clin Med9: E635, 2020PubMed10.3390/jcm9030635)| false
JansenRS, DuijstS, MahakenaS, SommerD, SzeriF, VáradiA,
et al.
: ABCC6-mediated ATP secretion by the liver is the main source of the mineralization inhibitor inorganic pyrophosphate in the systemic circulation-brief report. Arterioscler Thromb Vasc Biol34: 1985–1989, 2014PubMed
JansenRS, DuijstS, MahakenaS, SommerD, SzeriF, VáradiA, : ABCC6-mediated ATP secretion by the liver is the main source of the mineralization inhibitor inorganic pyrophosphate in the systemic circulation-brief report. Arterioscler Thromb Vasc Biol34: 1985–1989, 2014PubMed10.1161/ATVBAHA.114.304017)| false
RiserBL, BarretoFC, RezgR, ValaitisPW, CookCS, WhiteJA,
et al.
: Daily peritoneal administration of sodium pyrophosphate in a dialysis solution prevents the development of vascular calcification in a mouse model of uraemia. Nephrol Dial Transplant26: 3349–3357, 2011PubMed
RiserBL, BarretoFC, RezgR, ValaitisPW, CookCS, WhiteJA, : Daily peritoneal administration of sodium pyrophosphate in a dialysis solution prevents the development of vascular calcification in a mouse model of uraemia. Nephrol Dial Transplant26: 3349–3357, 2011PubMed10.1093/ndt/gfr039)| false
TaniT, FujiwaraM, OrimoH, ShimizuA, NarisawaS, PinkertonAB,
et al.
: Inhibition of tissue-nonspecific alkaline phosphatase protects against medial arterial calcification and improves survival probability in the CKD-MBD mouse model. J Pathol250: 30–41, 2020PubMed
PerellóJ, GómezM, FerrerMD, RodríguezNY, SalcedoC, BuadesJM,
et al.
: SNF472, a novel inhibitor of vascular calcification, could be administered during hemodialysis to attain potentially therapeutic phytate levels. J Nephrol31: 287–296, 2018PubMed
PerellóJ, GómezM, FerrerMD, RodríguezNY, SalcedoC, BuadesJM, : SNF472, a novel inhibitor of vascular calcification, could be administered during hemodialysis to attain potentially therapeutic phytate levels. J Nephrol31: 287–296, 2018PubMed10.1007/s40620-018-0471-9)| false
BrandenburgVM, SinhaS, TorregrosaJV, GargR, MillerS, CanalsAZ,
et al.
: Improvement in wound healing, pain, and quality of life after 12 weeks of SNF472 treatment: a phase 2 open-label study of patients with calciphylaxis. J Nephrol32: 811–821, 2019PubMed
BrandenburgVM, SinhaS, TorregrosaJV, GargR, MillerS, CanalsAZ, : Improvement in wound healing, pain, and quality of life after 12 weeks of SNF472 treatment: a phase 2 open-label study of patients with calciphylaxis. J Nephrol32: 811–821, 2019PubMed10.1007/s40620-019-00631-0)| false
KangJH, ToitaR, AsaiD, YamaokaT, MurataM: Reduction of inorganic phosphate-induced human smooth muscle cells calcification by inhibition of protein kinase A and p38 mitogen-activated protein kinase. Heart Vessels29: 718–722, 2014PubMed
KangJH, ToitaR, AsaiD, YamaokaT, MurataM: Reduction of inorganic phosphate-induced human smooth muscle cells calcification by inhibition of protein kinase A and p38 mitogen-activated protein kinase. Heart Vessels29: 718–722, 2014PubMed10.1007/s00380-013-0427-x)| false
FangY, GinsbergC, SeifertM, AgapovaO, SugataniT, RegisterTC,
et al.
: CKD-induced wingless/integration1 inhibitors and phosphorus cause the CKD-mineral and bone disorder. J Am Soc Nephrol25: 1760–1773, 2014PubMed
FangY, GinsbergC, SeifertM, AgapovaO, SugataniT, RegisterTC, : CKD-induced wingless/integration1 inhibitors and phosphorus cause the CKD-mineral and bone disorder. J Am Soc Nephrol25: 1760–1773, 2014PubMed10.1681/ASN.2013080818)| false
MoeSM, ChenNX, NewmanCL, OrganJM, KneisselM, KramerI,
et al.
: Anti-sclerostin antibody treatment in a rat model of progressive renal osteodystrophy. J Bone Miner Res30: 499–509, 2015PubMed
MoeSM, ChenNX, NewmanCL, OrganJM, KneisselM, KramerI, : Anti-sclerostin antibody treatment in a rat model of progressive renal osteodystrophy. J Bone Miner Res30: 499–509, 2015PubMed10.1002/jbmr.2372)| false
EvenepoelP, D’HaeseP, BrandenburgV: Sclerostin and DKK1: new players in renal bone and vascular disease. Kidney Int88: 235–240, 2015PubMed10.1038/ki.2015.156)| false
WilliamsMJ, SugataniT, AgapovaOA, FangY, GautJP, FaugereMC,
et al.
: The activin receptor is stimulated in the skeleton, vasculature, heart, and kidney during chronic kidney disease. Kidney Int93: 147–158, 2018PubMed
WilliamsMJ, SugataniT, AgapovaOA, FangY, GautJP, FaugereMC, : The activin receptor is stimulated in the skeleton, vasculature, heart, and kidney during chronic kidney disease. Kidney Int93: 147–158, 2018PubMed10.1016/j.kint.2017.06.016)| false
GravesenE, Lerche MaceM, NordholmA, Hofman-BangJ, HruskaK, Haagen NielsenC,
et al.
: Exogenous BMP7 in aortae of rats with chronic uremia ameliorates expression of profibrotic genes, but does not reverse established vascular calcification. PLoS One13: e0190820, 2018PubMed
GravesenE, Lerche MaceM, NordholmA, Hofman-BangJ, HruskaK, Haagen NielsenC, : Exogenous BMP7 in aortae of rats with chronic uremia ameliorates expression of profibrotic genes, but does not reverse established vascular calcification. PLoS One13: e0190820, 2018PubMed10.1371/journal.pone.0190820)| false
AgapovaOA, FangY, SugataniT, SeifertME, HruskaKA: Ligand trap for the activin type IIA receptor protects against vascular disease and renal fibrosis in mice with chronic kidney disease. Kidney Int89: 1231–1243, 2016PubMed
AgapovaOA, FangY, SugataniT, SeifertME, HruskaKA: Ligand trap for the activin type IIA receptor protects against vascular disease and renal fibrosis in mice with chronic kidney disease. Kidney Int89: 1231–1243, 2016PubMed10.1016/j.kint.2016.02.002)| false
ViegasC, AraújoN, MarreirosC, SimesD: The interplay between mineral metabolism, vascular calcification and inflammation in Chronic Kidney Disease (CKD): challenging old concepts with new facts. Aging (Albany NY)11: 4274–4299, 2019PubMed
ViegasC, AraújoN, MarreirosC, SimesD: The interplay between mineral metabolism, vascular calcification and inflammation in Chronic Kidney Disease (CKD): challenging old concepts with new facts. Aging (Albany NY)11: 4274–4299, 2019PubMed10.18632/aging.102046)| false
Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group: KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl (2011)7: 1–59, 2017PubMed
Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group: KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl (2011)7: 1–59, 2017PubMed)| false
OkunoS, IshimuraE, KitataniK, FujinoY, KohnoK, MaenoY,
et al.
: Presence of abdominal aortic calcification is significantly associated with all-cause and cardiovascular mortality in maintenance hemodialysis patients. Am J Kidney Dis49: 417–425, 2007PubMed
LewisJR, WongG, TavernitiA, Vucak-DzumhurM, ElderGJ: Association between Aortic Calcification, Cardiovascular Events, and Mortality in Kidney and Pancreas-Kidney Transplant Recipients. Am J Nephrol50: 177–186, 2019PubMed
LewisJR, WongG, TavernitiA, Vucak-DzumhurM, ElderGJ: Association between Aortic Calcification, Cardiovascular Events, and Mortality in Kidney and Pancreas-Kidney Transplant Recipients. Am J Nephrol50: 177–186, 2019PubMed10.1159/000502328)| false
PencakP, CzerwieńskaB, FicekR, WyskidaK, Kujawa-SzewieczekA, Olszanecka-GlinianowiczM,
et al.
: Calcification of coronary arteries and abdominal aorta in relation to traditional and novel risk factors of atherosclerosis in hemodialysis patients. BMC Nephrol14: 10, 2013PubMed
PencakP, CzerwieńskaB, FicekR, WyskidaK, Kujawa-SzewieczekA, Olszanecka-GlinianowiczM, : Calcification of coronary arteries and abdominal aorta in relation to traditional and novel risk factors of atherosclerosis in hemodialysis patients. BMC Nephrol14: 10, 2013PubMed10.1186/1471-2369-14-10)| false
CriquiMH, KamineniA, AllisonMA, IxJH, CarrJJ, CushmanM,
et al.
: Risk factor differences for aortic versus coronary calcified atherosclerosis: the multiethnic study of atherosclerosis. Arterioscler Thromb Vasc Biol30: 2289–2296, 2010PubMed
KauppilaLI, PolakJF, CupplesLA, HannanMT, KielDP, WilsonPW: New indices to classify location, severity and progression of calcific lesions in the abdominal aorta: a 25-year follow-up study. Atherosclerosis132: 245–250, 1997PubMed
KauppilaLI, PolakJF, CupplesLA, HannanMT, KielDP, WilsonPW: New indices to classify location, severity and progression of calcific lesions in the abdominal aorta: a 25-year follow-up study. Atherosclerosis132: 245–250, 1997PubMed10.1016/S0021-9150(97)00106-8)| false
ToussaintND, LauKK, StraussBJ, PolkinghorneKR, KerrPG: Determination and validation of aortic calcification measurement from lateral bone densitometry in dialysis patients. Clin J Am Soc Nephrol4: 119–127, 2009PubMed
ToussaintND, LauKK, StraussBJ, PolkinghorneKR, KerrPG: Determination and validation of aortic calcification measurement from lateral bone densitometry in dialysis patients. Clin J Am Soc Nephrol4: 119–127, 2009PubMed10.2215/CJN.03410708)| false
AleksovaJ, KurniawanS, Vucak-DzumhurM, KerrP, EbelingPR, MilatF,
et al.
: Aortic vascular calcification is inversely associated with the trabecular bone score in patients receiving dialysis. Bone113: 118–123, 2018PubMed
FoxCS, LarsonMG, VasanRS, GuoCY, PariseH, LevyD,
et al.
: Cross-sectional association of kidney function with valvular and annular calcification: the Framingham heart study. J Am Soc Nephrol17: 521–527, 2006PubMed
FoxCS, LarsonMG, VasanRS, GuoCY, PariseH, LevyD, : Cross-sectional association of kidney function with valvular and annular calcification: the Framingham heart study. J Am Soc Nephrol17: 521–527, 2006PubMed10.1681/ASN.2005060627)| false
FarrarDJ, BondMG, RileyWA, SawyerJK: Anatomic correlates of aortic pulse wave velocity and carotid artery elasticity during atherosclerosis progression and regression in monkeys. Circulation83: 1754–1763, 1991PubMed
KrishnasamyR, TanSJ, HawleyCM, JohnsonDW, StantonT, LeeK,
et al.
: Progression of arterial stiffness is associated with changes in bone mineral markers in advanced CKD. BMC Nephrol18: 281, 2017PubMed
KrishnasamyR, TanSJ, HawleyCM, JohnsonDW, StantonT, LeeK, : Progression of arterial stiffness is associated with changes in bone mineral markers in advanced CKD. BMC Nephrol18: 281, 2017PubMed10.1186/s12882-017-0705-4)| false
FordML, TomlinsonLA, ChapmanTP, RajkumarC, HoltSG: Aortic stiffness is independently associated with rate of renal function decline in chronic kidney disease stages 3 and 4. Hypertension55: 1110–1115, 2010PubMed
FordML, TomlinsonLA, ChapmanTP, RajkumarC, HoltSG: Aortic stiffness is independently associated with rate of renal function decline in chronic kidney disease stages 3 and 4. Hypertension55: 1110–1115, 2010PubMed10.1161/HYPERTENSIONAHA.109.143024)| false
KamathTP, PrasadR, AllisonMA, CriquiMC, IxJH, RifkinDE,
et al.
: Association of Ankle-Brachial and Toe-Brachial Indexes With Mortality in Patients With CKD. Kidney Med2: 68–75, 2020PubMed
KamathTP, PrasadR, AllisonMA, CriquiMC, IxJH, RifkinDE, : Association of Ankle-Brachial and Toe-Brachial Indexes With Mortality in Patients With CKD. Kidney Med2: 68–75, 2020PubMed10.1016/j.xkme.2019.11.001)| false
YoshitomiR, NakayamaM, UraY, KumaK, NishimotoH, FukuiA,
et al.
: Ankle-brachial blood pressure index predicts cardiovascular events and mortality in Japanese patients with chronic kidney disease not on dialysis. Hypertens Res37: 1050–1055, 2014PubMed
YoshitomiR, NakayamaM, UraY, KumaK, NishimotoH, FukuiA, : Ankle-brachial blood pressure index predicts cardiovascular events and mortality in Japanese patients with chronic kidney disease not on dialysis. Hypertens Res37: 1050–1055, 2014PubMed10.1038/hr.2014.120)| false
GuX, ManC, ZhangH, FanY: High ankle-brachial index and risk of cardiovascular or all-cause mortality: A meta-analysis. Atherosclerosis282: 29–36, 2019PubMed
GuX, ManC, ZhangH, FanY: High ankle-brachial index and risk of cardiovascular or all-cause mortality: A meta-analysis. Atherosclerosis282: 29–36, 2019PubMed10.1016/j.atherosclerosis.2018.12.028)| false
PaschA, FareseS, GräberS, WaldJ, RichteringW, FloegeJ,
et al.
: Nanoparticle-based test measures overall propensity for calcification in serum. J Am Soc Nephrol23: 1744–1752, 2012PubMed
BressendorffI, HansenD, SchouM, PaschA, BrandiL: The Effect of Increasing Dialysate Magnesium on Serum Calcification Propensity in Subjects with End Stage Kidney Disease: A Randomized, Controlled Clinical Trial. Clin J Am Soc Nephrol13: 1373–1380, 2018PubMed
BressendorffI, HansenD, SchouM, PaschA, BrandiL: The Effect of Increasing Dialysate Magnesium on Serum Calcification Propensity in Subjects with End Stage Kidney Disease: A Randomized, Controlled Clinical Trial. Clin J Am Soc Nephrol13: 1373–1380, 2018PubMed10.2215/CJN.13921217)| false
Ter MeulenKJ, DekkerMJE, PaschA, BroersNJH, van der SandeFM, van der NetJB,
et al.
: Citric-acid dialysate improves the calcification propensity of hemodialysis patients: A multicenter prospective randomized cross-over trial. PLoS One14: e0225824, 2019PubMed
Ter MeulenKJ, DekkerMJE, PaschA, BroersNJH, van der SandeFM, van der NetJB, : Citric-acid dialysate improves the calcification propensity of hemodialysis patients: A multicenter prospective randomized cross-over trial. PLoS One14: e0225824, 2019PubMed10.1371/journal.pone.0225824)| false
SpiegelDM, BradyK: Calcium balance in normal individuals and in patients with chronic kidney disease on low- and high-calcium diets. Kidney Int81: 1116–1122, 2012PubMed
SpiegelDM, BradyK: Calcium balance in normal individuals and in patients with chronic kidney disease on low- and high-calcium diets. Kidney Int81: 1116–1122, 2012PubMed10.1038/ki.2011.490)| false
ToussaintND, PedagogosE, LioufasNM, ElderGJ, PascoeEM, BadveSV,
et al.
; IMPROVE-CKD Trial Investigators: A Randomized Trial on the Effect of Phosphate Reduction on Vascular End Points in CKD (IMPROVE-CKD). J Am Soc Nephrol31: 2653–2666, 2020PubMed
ToussaintND, PedagogosE, LioufasNM, ElderGJ, PascoeEM, BadveSV, ; IMPROVE-CKD Trial Investigators: A Randomized Trial on the Effect of Phosphate Reduction on Vascular End Points in CKD (IMPROVE-CKD). J Am Soc Nephrol31: 2653–2666, 2020PubMed10.1681/ASN.2020040411)| false
PalmerSC, GardnerS, TonelliM, MavridisD, JohnsonDW, CraigJC,
et al.
: Phosphate-Binding Agents in Adults With CKD: A Network Meta-analysis of Randomized Trials. Am J Kidney Dis68: 691–702, 2016PubMed
PatelL, BernardLM, ElderGJ: Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials. Clin J Am Soc Nephrol11: 232–244, 2016PubMed
PatelL, BernardLM, ElderGJ: Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials. Clin J Am Soc Nephrol11: 232–244, 2016PubMed10.2215/CJN.06800615)| false
BlockGA, BlockMS, SmitsG, MehtaR, IsakovaT, WolfM,
et al.
: A Pilot Randomized Trial of Ferric Citrate Coordination Complex for the Treatment of Advanced CKD. J Am Soc Nephrol30: 1495–1504, 2019PubMed
BlockGA, BlockMS, SmitsG, MehtaR, IsakovaT, WolfM, : A Pilot Randomized Trial of Ferric Citrate Coordination Complex for the Treatment of Advanced CKD. J Am Soc Nephrol30: 1495–1504, 2019PubMed10.1681/ASN.2018101016)| false
de FranciscoAL, LeidigM, CovicAC, KettelerM, Benedyk-LorensE, MircescuGM,
et al.
: Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability. Nephrol Dial Transplant25: 3707–3717, 2010PubMed
de FranciscoAL, LeidigM, CovicAC, KettelerM, Benedyk-LorensE, MircescuGM, : Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability. Nephrol Dial Transplant25: 3707–3717, 2010PubMed10.1093/ndt/gfq292)| false
Ter BraakeAD, TinnemansPT, ShanahanCM, HoenderopJGJ, de BaaijJHF: Magnesium prevents vascular calcification in vitro by inhibition of hydroxyapatite crystal formation. Sci Rep8: 2069, 2018PubMed
Ter BraakeAD, TinnemansPT, ShanahanCM, HoenderopJGJ, de BaaijJHF: Magnesium prevents vascular calcification in vitro by inhibition of hydroxyapatite crystal formation. Sci Rep8: 2069, 2018PubMed10.1038/s41598-018-20241-3)| false
Montes de OcaA, GuerreroF, Martinez-MorenoJM, MadueñoJA, HerenciaC, PeraltaA,
et al.
: Magnesium inhibits Wnt/β-catenin activity and reverses the osteogenic transformation of vascular smooth muscle cells. PLoS One9: e89525, 2014PubMed
HerenciaC, Rodríguez-OrtizME, Muñoz-CastañedaJR, Martinez-MorenoJM, CanalejoR, Montes de OcaA,
et al.
: Angiotensin II prevents calcification in vascular smooth muscle cells by enhancing magnesium influx. Eur J Clin Invest45: 1129–1144, 2015PubMed
SalemS, BruckH, BahlmannFH, PeterM, Passlick-DeetjenJ, KretschmerA,
et al.
: Relationship between magnesium and clinical biomarkers on inhibition of vascular calcification. Am J Nephrol35: 31–39, 2012PubMed
SalemS, BruckH, BahlmannFH, PeterM, Passlick-DeetjenJ, KretschmerA, : Relationship between magnesium and clinical biomarkers on inhibition of vascular calcification. Am J Nephrol35: 31–39, 2012PubMed10.1159/000334742)| false
XiongJ, HeT, WangM, NieL, ZhangY, WangY,
et al.
: Serum magnesium, mortality, and cardiovascular disease in chronic kidney disease and end-stage renal disease patients: a systematic review and meta-analysis. J Nephrol32: 791–802, 2019PubMed
SakaguchiY, HamanoT, ObiY, MondenC, OkaT, YamaguchiS,
et al.
: A Randomized Trial of Magnesium Oxide and Oral Carbon Adsorbent for Coronary Artery Calcification in Predialysis CKD. J Am Soc Nephrol30: 1073–1085, 2019PubMed
BressendorffI, HansenD, SchouM, KragelundC, BrandiL: The effect of magnesium supplementation on vascular calcification in chronic kidney disease-a randomised clinical trial (MAGiCAL-CKD): essential study design and rationale. BMJ Open7: e016795, 2017PubMed
LiabeufS, BourronO, VemeerC, TheuwissenE, MagdeleynsE,
et al.
: Vascular calcification in patients with type 2 diabetes: the involvement of matrix Gla protein. Cardiovasc Diabetol13: 85, 2014PubMed
LiabeufS, BourronO, VemeerC, TheuwissenE, MagdeleynsE, : Vascular calcification in patients with type 2 diabetes: the involvement of matrix Gla protein. Cardiovasc Diabetol13: 85, 2014PubMed10.1186/1475-2840-13-85)| false
NigwekarSU, BlochDB, NazarianRM, VermeerC, BoothSL, XuD,
et al.
: Vitamin K-Dependent Carboxylation of Matrix Gla Protein Influences the Risk of Calciphylaxis. J Am Soc Nephrol28: 1717–1722, 2017PubMed
WestenfeldR, KruegerT, SchlieperG, CranenburgEC, MagdeleynsEJ, HeidenreichS,
et al.
: Effect of vitamin K2 supplementation on functional vitamin K deficiency in hemodialysis patients: a randomized trial. Am J Kidney Dis59: 186–195, 2012PubMed
WestenfeldR, KruegerT, SchlieperG, CranenburgEC, MagdeleynsEJ, HeidenreichS, : Effect of vitamin K2 supplementation on functional vitamin K deficiency in hemodialysis patients: a randomized trial. Am J Kidney Dis59: 186–195, 2012PubMed10.1053/j.ajkd.2011.10.041)| false
KruegerT, SchlieperG, SchurgersL, CornelisT, CozzolinoM, JacobiJ,
et al.
: Vitamin K1 to slow vascular calcification in haemodialysis patients (VitaVasK trial): a rationale and study protocol. Nephrol Dial Transplant29: 1633–1638, 2014PubMed
GeleijnseJM, VermeerC, GrobbeeDE, SchurgersLJ, KnapenMH, van der MeerIM,
et al.
: Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: the Rotterdam Study. J Nutr134: 3100–3105, 2004PubMed
GeleijnseJM, VermeerC, GrobbeeDE, SchurgersLJ, KnapenMH, van der MeerIM, : Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: the Rotterdam Study. J Nutr134: 3100–3105, 2004PubMed10.1093/jn/134.11.3100)| false
ToussaintND, LauKK, StraussBJ, PolkinghorneKR, KerrPG: Effect of alendronate on vascular calcification in CKD stages 3 and 4: a pilot randomized controlled trial. Am J Kidney Dis56: 57–68, 2010PubMed
ToussaintND, LauKK, StraussBJ, PolkinghorneKR, KerrPG: Effect of alendronate on vascular calcification in CKD stages 3 and 4: a pilot randomized controlled trial. Am J Kidney Dis56: 57–68, 2010PubMed10.1053/j.ajkd.2009.12.039)| false
MolostvovG, JamesS, FletcherS, BennettJ, LehnertH, BlandR,
et al.
: Extracellular calcium-sensing receptor is functionally expressed in human artery. Am J Physiol Renal Physiol293: F946–F955, 2007PubMed
Ureña-TorresPA, FloegeJ, HawleyCM, PedagogosE, GoodmanWG, PétavyF,
et al.
: Protocol adherence and the progression of cardiovascular calcification in the ADVANCE study. Nephrol Dial Transplant28: 146–152, 2013PubMed
Ureña-TorresPA, FloegeJ, HawleyCM, PedagogosE, GoodmanWG, PétavyF, : Protocol adherence and the progression of cardiovascular calcification in the ADVANCE study. Nephrol Dial Transplant28: 146–152, 2013PubMed10.1093/ndt/gfs356)| false
CozzolinoM, CiceriP, GalassiA, ManganoM, CarugoS, CapelliI,
et al.
: The Key Role of Phosphate on Vascular Calcification. Toxins (Basel)11: E213, 2019PubMed
CozzolinoM, CiceriP, GalassiA, ManganoM, CarugoS, CapelliI, : The Key Role of Phosphate on Vascular Calcification. Toxins (Basel)11: E213, 2019PubMed10.3390/toxins11040213)| false
de OliveiraRB, StinghenAEM, MassyZA: Vitamin K role in mineral and bone disorder of chronic kidney disease. Clin Chim Acta502: 66–72, 2020PubMed10.1016/j.cca.2019.11.040)| false
